|
|
| PMID |
|
|
| TITLE |
|
| Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. |
|
| ABSTRACT |
|
| Aim |
NlmCategory: UNASSIGNED |
| Substance use disorders (SUD) result in substantial morbidity and mortality worldwide. Opioids, and to a lesser extent cocaine, contribute to a large percentage of this health burden. Despite their high heritability, few genetic risk loci have been identified for either opioid or cocaine dependence (OD or CD, respectively). A genome-wide association study of OD and CD related phenotypes reflecting the time between first self-reported use of these substances and a first DSM-IV dependence diagnosis was conducted. |
| Methods |
NlmCategory: UNASSIGNED |
| Substance use disorders (SUD) result in substantial morbidity and mortality worldwide. Opioids, and to a lesser extent cocaine, contribute to a large percentage of this health burden. Despite their high heritability, few genetic risk loci have been identified for either opioid or cocaine dependence (OD or CD, respectively). A genome-wide association study of OD and CD related phenotypes reflecting the time between first self-reported use of these substances and a first DSM-IV dependence diagnosis was conducted. Cox proportional hazards regression in a discovery sample of 6,188 African-Americans (AAs) and 6,835 European-Americans (EAs) participants in a genetic study of multiple substance dependence phenotypes were used to test for association between genetic variants and these outcomes. The top findings were tested for replication in two independent cohorts. |
| Results |
NlmCategory: UNASSIGNED |
| Substance use disorders (SUD) result in substantial morbidity and mortality worldwide. Opioids, and to a lesser extent cocaine, contribute to a large percentage of this health burden. Despite their high heritability, few genetic risk loci have been identified for either opioid or cocaine dependence (OD or CD, respectively). A genome-wide association study of OD and CD related phenotypes reflecting the time between first self-reported use of these substances and a first DSM-IV dependence diagnosis was conducted. Cox proportional hazards regression in a discovery sample of 6,188 African-Americans (AAs) and 6,835 European-Americans (EAs) participants in a genetic study of multiple substance dependence phenotypes were used to test for association between genetic variants and these outcomes. The top findings were tested for replication in two independent cohorts. In the discovery sample, three independent regions containing variants associated with time to dependence at < 5 x 10 were identified, one (rs61835088 = 1.03 x 10 ) for cocaine in the combined EA-AA meta-analysis in the gene on chromosome 1, and two for opioids in the AA portion of the sample in intergenic regions of chromosomes 4 (rs4860439, = 1.37 x 10 ) and 9 (rs7032521, = 3.30 x 10 ). After meta-analysis with data from the replication cohorts, the signal at rs61835088 improved (HR = 0.87, = 3.71 x 10 and an intergenic SNP on chromosome 21 (rs2825295, HR = 1.14, = 2.57 x 10 ) that missed the significance threshold in the AA discovery sample became genome-wide significant (GWS) for CD. |
| Conclusions |
NlmCategory: UNASSIGNED |
| Substance use disorders (SUD) result in substantial morbidity and mortality worldwide. Opioids, and to a lesser extent cocaine, contribute to a large percentage of this health burden. Despite their high heritability, few genetic risk loci have been identified for either opioid or cocaine dependence (OD or CD, respectively). A genome-wide association study of OD and CD related phenotypes reflecting the time between first self-reported use of these substances and a first DSM-IV dependence diagnosis was conducted. Cox proportional hazards regression in a discovery sample of 6,188 African-Americans (AAs) and 6,835 European-Americans (EAs) participants in a genetic study of multiple substance dependence phenotypes were used to test for association between genetic variants and these outcomes. The top findings were tested for replication in two independent cohorts. In the discovery sample, three independent regions containing variants associated with time to dependence at < 5 x 10 were identified, one (rs61835088 = 1.03 x 10 ) for cocaine in the combined EA-AA meta-analysis in the gene on chromosome 1, and two for opioids in the AA portion of the sample in intergenic regions of chromosomes 4 (rs4860439, = 1.37 x 10 ) and 9 (rs7032521, = 3.30 x 10 ). After meta-analysis with data from the replication cohorts, the signal at rs61835088 improved (HR = 0.87, = 3.71 x 10 and an intergenic SNP on chromosome 21 (rs2825295, HR = 1.14, = 2.57 x 10 ) that missed the significance threshold in the AA discovery sample became genome-wide significant (GWS) for CD. Although the two GWS variants are not in genes with obvious links to SUD biology and have modest effect sizes, they are statistically robust and show evidence for association in independent samples. These results may point to novel pathways contributing to disease progression and highlight the utility of related phenotypes to better understand the genetics of SUDs. |
|
| DATE PUBLISHED |
|
|
| HISTORY |
|
| PUBSTATUS |
PUBSTATUSDATE |
| entrez |
2021/06/14 09:59 |
| pubmed |
2021/06/15 06:00 |
| medline |
2021/06/15 06:01 |
|
| AUTHORS |
|
| NAME |
COLLECTIVENAME |
LASTNAME |
FORENAME |
INITIALS |
AFFILIATION |
AFFILIATIONINFO |
| Sherva R |
|
Sherva |
Richard |
R |
|
Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA 02118, USA. |
| Zhu C |
|
Zhu |
Congcong |
C |
|
Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA 02118, USA. |
| Wetherill L |
|
Wetherill |
Leah |
L |
|
Department of Medical and Molecular Genetics and Biochemistry, Indiana University School of Medicine, Indianapolis, IN 46202, USA. |
| Edenberg HJ |
|
Edenberg |
Howard J |
HJ |
|
Department of Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. |
| Johnson E |
|
Johnson |
Emma |
E |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO 63110, USA. |
| Degenhardt L |
|
Degenhardt |
Louisa |
L |
|
National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. |
| Agrawal A |
|
Agrawal |
Arpana |
A |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO 63110, USA. |
| Martin NG |
|
Martin |
Nicholas G |
NG |
|
Queensland Institute of Medical Research Berghofer, Brisbane, QLD 4006, Australia. |
| Nelson E |
|
Nelson |
Elliot |
E |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO 63110, USA. |
| Kranzler HR |
|
Kranzler |
Henry R |
HR |
|
Perelman School of Medicine, University of Pennsylvania and VISN 4 MIRECC, Crescenz VAMC, Philadelphia, PA 19104, USA. |
| Gelernter J |
|
Gelernter |
Joel |
J |
|
Department of Psychiatry, VA CT Healthcare Center, West Haven, CT 06516, USA. |
| Farrer LA |
|
Farrer |
Lindsay A |
LA |
|
Department of Biostatistics, Boston University School Public Health, Boston, MA 02118, USA. |
|
| INVESTIGATORS |
|
|
| JOURNAL |
|
| VOLUME: 2 |
| ISSUE: |
| TITLE: Exploration of medicine |
| ISOABBREVIATION: Explor Med |
| YEAR: 2021 |
| MONTH: |
| DAY: |
| MEDLINEDATE: |
| SEASON: |
| CITEDMEDIUM: Internet |
| ISSN: 2692-3106 |
| ISSNTYPE: Electronic |
|
| MEDLINE JOURNAL |
|
| MEDLINETA: Explor Med |
| COUNTRY: United States |
| ISSNLINKING: 2692-3106 |
| NLMUNIQUEID: 101765387 |
|
| PUBLICATION TYPE |
|
| PUBLICATIONTYPE TEXT |
| Journal Article |
|
| COMMENTS AND CORRECTIONS |
|
|
| GRANTS |
|
|
| GENERAL NOTE |
|
|
| KEYWORDS |
|
| KEYWORD |
| FAM78B |
| GWAS |
| Substance use disorders |
| cocaine use disorders |
| genetics |
| opioid use disorders |
|
| MESH HEADINGS |
|
|
| SUPPLEMENTARY MESH |
|
|
| GENE SYMBOLS |
|
|
| CHEMICALS |
|
|
| OTHER ID's |
|
|
|
